CONCORD NEWS IN YOUR INBOX: SIGN UP HERE

Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by InnoCare Pharma

< Previous 1 2 Next >
News headline image
InnoCare Announces Key Developments of Critical Clinical Studies
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China
From InnoCare Pharma
Via GlobeNewswire
News headline image
Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China
From InnoCare Pharma
Via GlobeNewswire
News headline image
Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
From InnoCare Pharma
Via GlobeNewswire
News headline image
Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces First Patient Dosed in Clinical Trial of Novel ADC ICP-B794 in China
From InnoCare Pharma
Via GlobeNewswire
News headline image
Latest Data of InnoCare's Zurletrectinib Orally Presented at SIOP 2025
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Announces First Patient Dosed in the Registrational Trial of BCL2 Inhibitor Mesutoclax for Treatment of BTKi-treated MCL Patients in China
From InnoCare Pharma
Via GlobeNewswire
News headline image
InnoCare Releases 2025 Interim Results and Business Highlights
From InnoCare Pharma
Via Business Wire
News headline image
InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China
From InnoCare Pharma
Via Business Wire
News headline image
Data of InnoCare’s Robust Hemato-Oncology Pipelines Presented at the European Hematology Association (EHA) 2025 Congress
From InnoCare Pharma
Via Business Wire
News headline image
Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2025 ASCO Annual Meeting
From InnoCare Pharma
Via Business Wire
News headline image
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor Mesutoclax for Myelodysplastic Syndromes in China
From InnoCare Pharma
Via Business Wire
News headline image
InnoCare Announces the Approval of Minjuvi® (Tafasitamab) in Combination with Lenalidomide for the treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
From InnoCare Pharma
Via Business Wire
News headline image
InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China
From InnoCare Pharma
Via Business Wire
News headline image
InnoCare’s Mesutoclax Receives Breakthrough Therapy Designation from China’s NMPA
From InnoCare Pharma
Via Business Wire
News headline image
InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA
From InnoCare Pharma
Via Business Wire
News headline image
InnoCare Announces Approval of Orelabrutinib for the First-line Treatment of CLL/SLL in China
From InnoCare Pharma
Via Business Wire
News headline image
InnoCare Announces the Acceptance of New Drug Application for pan-TRK Inhibitor Zurletrectinib in China
From InnoCare Pharma
Via Business Wire
News headline image
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China
From InnoCare Pharma
Via Business Wire
News headline image
InnoCare Releases 2024 Results and Business Highlights
From InnoCare Pharma
Via Business Wire
News headline image
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of ICP-488 for the Treatment of Psoriasis in China
From InnoCare Pharma
Via Business Wire
News headline image
Data of InnoCare's ICP-488 for the Treatment of Psoriasis Presented at Late Breaking Oral Presentation of 2025 AAD
From InnoCare Pharma
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article